CRNX
Price
$29.76
Change
-$0.35 (-1.16%)
Updated
May 23 closing price
Capitalization
2.79B
76 days until earnings call
RYTM
Price
$62.36
Change
+$0.35 (+0.56%)
Updated
May 23 closing price
Capitalization
3.97B
73 days until earnings call
Interact to see
Advertisement

CRNX vs RYTM

Header iconCRNX vs RYTM Comparison
Open Charts CRNX vs RYTMBanner chart's image
Crinetics Pharmaceuticals
Price$29.76
Change-$0.35 (-1.16%)
Volume$740.33K
Capitalization2.79B
Rhythm Pharmaceuticals
Price$62.36
Change+$0.35 (+0.56%)
Volume$392.05K
Capitalization3.97B
CRNX vs RYTM Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. RYTM commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and RYTM is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (CRNX: $29.76 vs. RYTM: $62.36)
Brand notoriety: CRNX and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 72% vs. RYTM: 50%
Market capitalization -- CRNX: $2.79B vs. RYTM: $3.97B
CRNX [@Biotechnology] is valued at $2.79B. RYTM’s [@Biotechnology] market capitalization is $3.97B. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileRYTM’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • RYTM’s FA Score: 1 green, 4 red.
According to our system of comparison, RYTM is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 3 TA indicator(s) are bullish while RYTM’s TA Score has 4 bullish TA indicator(s).

  • CRNX’s TA Score: 3 bullish, 5 bearish.
  • RYTM’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, RYTM is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а -4.74% price change this week, while RYTM (@Biotechnology) price change was +4.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

CRNX is expected to report earnings on Aug 08, 2025.

RYTM is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($3.97B) has a higher market cap than CRNX($2.79B). RYTM YTD gains are higher at: 11.397 vs. CRNX (-41.795). RYTM has higher annual earnings (EBITDA): -145.8M vs. CRNX (-373.49M). CRNX has more cash in the bank: 1.27B vs. RYTM (314M). RYTM has less debt than CRNX: RYTM (4.06M) vs CRNX (50.8M). RYTM has higher revenues than CRNX: RYTM (137M) vs CRNX (760K).
CRNXRYTMCRNX / RYTM
Capitalization2.79B3.97B70%
EBITDA-373.49M-145.8M256%
Gain YTD-41.79511.397-367%
P/E RatioN/AN/A-
Revenue760K137M1%
Total Cash1.27B314M406%
Total Debt50.8M4.06M1,250%
FUNDAMENTALS RATINGS
CRNX vs RYTM: Fundamental Ratings
CRNX
RYTM
OUTLOOK RATING
1..100
1214
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
6834
SMR RATING
1..100
5199
PRICE GROWTH RATING
1..100
8643
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (92) in the Pharmaceuticals Major industry is in the same range as RYTM (96) in the Biotechnology industry. This means that CRNX’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (34) in the Biotechnology industry is somewhat better than the same rating for CRNX (68) in the Pharmaceuticals Major industry. This means that RYTM’s stock grew somewhat faster than CRNX’s over the last 12 months.

CRNX's SMR Rating (51) in the Pharmaceuticals Major industry is somewhat better than the same rating for RYTM (99) in the Biotechnology industry. This means that CRNX’s stock grew somewhat faster than RYTM’s over the last 12 months.

RYTM's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for CRNX (86) in the Pharmaceuticals Major industry. This means that RYTM’s stock grew somewhat faster than CRNX’s over the last 12 months.

RYTM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that RYTM’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXRYTM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 17 days ago
77%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 19 days ago
80%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
75%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HIX4.100.02
+0.49%
Western Asset High Income Fund II
AUDJPY92.470.27
+0.29%
Australian Dollar - Japan Yen
MSTB35.47N/A
N/A
LHA Market State Tactical Beta ETF
CNYNZD0.23-0.00
-0.58%
China Yuan - New Zealand Dollar
DFSU36.89-0.31
-0.83%
Dimensional US Sustainability Core 1 ETF

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-1.16%
XNCR - CRNX
58%
Loosely correlated
-1.56%
IDYA - CRNX
56%
Loosely correlated
-1.72%
RVMD - CRNX
55%
Loosely correlated
+2.50%
TRDA - CRNX
55%
Loosely correlated
-1.57%
KRYS - CRNX
54%
Loosely correlated
-1.29%
More